Immunosuppressive therapy in atopic dermatitis

The treatment of patients with atopic dermatitis poses significant challenges for physicians due to the complexity of the disease's immunopathogenesis, its chronic nature, persistent itching, and the unpredictability of individual disease progression. Additionally, the issue of insufficient patient adherence to prescribed treatment further complicates the therapeutic process.

This article presents an expanded overview of the effectiveness of the main systemic immunosuppressive agents currently used to treat patients with moderate atopic dermatitis. The medications discussed include cyclosporine A, methotrexate, azathioprine, and phototherapy, which is frequently employed in clinical practice. Attention is given to their clinical efficacy, dose-dependent effectiveness, as well as the influence of the patient's phototype on treatment outcomes and potential side effects. The article also explores the prospects for enhancing clinical effectiveness and reducing the risk of adverse events through the combined use of various immunosuppressive agents, including phototherapy. This approach not only has the potential to improve treatment outcomes but also to expand the therapeutic options available to physicians, allowing for more effective management of disease manifestations and improved quality of life for patients. In conclusion, the importance of an individualized approach to each patient is emphasized, as it may contribute to more successful symptom control, a reduction in the frequency of exacerbations, and an overall increase in patient satisfaction with the therapy provided.